Loxidol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loxidol

Quick Facts

Property Description
Active ingredient Meloxicam
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Forms Tablet, capsule, oral suspension, solution for injection
Common use Anti-inflammatory, analgesic (pain relief), antipyretic (fever reducer)
Origin Synthetic, Oxicam derivative

Identity, Class, and Composition

Loxidol is the trade name for a prescription-only medicine containing the active ingredient Meloxicam, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This single active ingredient product is a synthetic oxicam derivative belonging to the enolic acid group, establishing its core pharmacological identity. As an NSAID, Meloxicam is chemically recognized for targeting pain and inflammation within the body's tissues, contrasting with opioid-based medications which act primarily on the central nervous system.

The Active Ingredient and General Purpose

Meloxicam's general purpose is to function as a multi-action agent, providing relief as an anti-inflammatory agent, a pain reliever, and a fever reducer. This therapeutic profile is achieved through its primary mechanism as a preferential COX-2 inhibitor, meaning it chiefly works by blocking the synthesis of prostaglandins, the compounds that signal swelling, pain, and heat. This mechanism of action is effective for reducing swelling and alleviating pain. Therefore, the medication’s main function is to reduce physical discomfort associated with inflammatory conditions, such as rheumatic diseases.

Available Forms and Route of Administration

Loxidol is made available in several dosage forms to accommodate patient needs, including tablets, capsules, oral suspension, and a sterile solution for intravenous injection. The availability of both oral and intravenous preparations is a key factor, enabling flexible administration based on the patient's condition. The preparation is composed of the active substance Meloxicam within a foundational vehicle, such as an aqueous base for the injectable form or a solid excipient matrix for the oral formulations.

Regulatory References

  1. EMA Meloxicam Public Assessment Report

What side effects are possible with Loxidol?

Possible Side Effects and Safety Information

The safety profile for Loxidol (Meloxicam) is officially documented by government regulatory bodies, detailing potential adverse reactions and safety constraints, organized by frequency and affected body system. Common effects are generally classified as affecting the Gastrointestinal System, including very common reactions such as dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, and diarrhoea. Other system-organ classes involved include Blood and Lymphatic System Disorders, Nervous System Disorders (e.g., headache, dizziness), and Skin and Subcutaneous Tissue Disorders.

Documented Serious Adverse Reactions

The official labeling highlights risks for serious, potentially fatal events, which often accompany the use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs):

  • Cardiovascular Risks: Increased risk of serious arterial thrombotic events, including Myocardial Infarction (MI) and Stroke. This risk may be associated with longer duration of use.
  • Gastrointestinal Risks: Increased risk of serious gastrointestinal bleeding, ulceration, and perforation of the stomach or intestines. These events can occur at any time, often without warning symptoms.
  • Cutaneous Reactions: Rare but severe, life-threatening skin adverse reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported, with the highest risk noted within the first month of treatment.

Population-Specific Safety Notes

The regulatory profile includes constraints for specific groups. Older adults are at a higher risk for serious gastrointestinal adverse events. Use is contraindicated in patients with severe renal impairment not on dialysis and in those with severely impaired liver function. Additionally, the medicine must be avoided from 30 weeks of gestation and later due to risks to the fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes potential manifestations of Loxidol (meloxicam) overdose, emphasizing the need to seek medical attention immediately should an overdose be suspected. While initial, generally reversible symptoms may include nausea, vomiting, epigastric pain, lethargy, and drowsiness, the official labeling documents the risk of severe poisoning.

Documented High-Risk Outcomes

Overdose has the potential to lead to life-threatening outcomes, including acute renal failure, hepatic dysfunction, cardiovascular collapse, coma, and cardiac arrest. The official guidance from regulatory authorities confirms that management must consist of symptomatic and supportive care, as no specific antidote is known for meloxicam overdose.

Emergency Management

Action Regulatory Description
Help-Seeking Requirement Seek medical attention immediately for suspected overdose.
Supportive Measures Symptomatic and supportive care is mandated.
Procedural Interventions Administration of activated charcoal is recommended within one to two hours of overdose.
Monitoring Requirement Monitoring of renal function and liver function should be instituted due to the documented risk of severe organ damage.

Immediate medical care is required to address the potential for severe systemic complications and to institute appropriate supportive measures as described in the product's official prescribing information.

Therapeutic Uses of Loxidol

What Loxidol Treats: Main Uses and Benefits

Loxidol is considered relevant for supportive relief for symptoms associated with chronic inflammatory and degenerative joint diseases in adults, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). Use is directed toward the management of symptoms of these major conditions. It is also considered relevant for the management of specific forms of Juvenile Rheumatoid Arthritis (JRA) in pediatric patients aged 2 years and older.

This medication helps address symptom clusters that may create noticeable functional strain, particularly moderate-to-severe pain, joint swelling, and tenderness. Applied in clinical settings that involve acute or unstable symptom patterns, it provides support that contributes to easing the overall symptom load, especially during flares of chronic conditions or in managing post-operative discomfort.

By relieving pain and reducing inflammation, Loxidol generally assists with easing symptoms related to joint stiffness and functional strain. This provides supportive relief when symptoms interfere with routine activities and may assist with maintaining functional stability.


Quick Fact: Supportive Relief for Inflammatory Symptoms

Category Relief Provided
Key Symptoms Addressed Pain, Swelling, Tenderness, Stiffness
Use Context Chronic arthritis management, Post-operative discomfort
Supports Patient Comfort May assist with maintaining functional stability and comfort

Regulatory References

  1. NIH National Library of Medicine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Loxidol (Meloxicam) — Official Regulatory Information

The eligibility for Loxidol, which contains the active ingredient Meloxicam, is strictly defined by regulatory documents based on age, existing health conditions, and reproductive status.


Eligibility Scope Criteria from Regulatory Documents
Populations Allowed Adults for relief of signs and symptoms of Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Pediatric patients 2 years of age and older for specific forms of Juvenile Rheumatoid Arthritis (JRA).
Populations Contraindicated Patients with known hypersensitivity to meloxicam, aspirin, or other NSAIDs; those with active peptic ulceration/hemorrhage; patients with severe uncontrolled heart failure; those with severe non-dialyzed renal failure; and patients in the third trimester of pregnancy.
Age-Related Rules Contraindicated in children and adolescents under 16 years of age for adult indications. Use in older adults is permitted but requires caution due to explicitly labeled increased risks.
Condition-Specific Restrictions Contraindicated for peri-operative pain in the setting of CABG surgery and in patients with aspirin-sensitive asthma. Use in patients on hemodialysis is restricted to a lower maximum daily dosage.
Pregnancy and Lactation Contraindicated in the third trimester; restricted use is advised between 20 and 30 weeks gestation. Use during lactation is cautioned as the drug may be excreted in human milk.

Official regulatory labeling dictates that use is contraindicated if a patient has specific severe comorbidities or is in a prohibited physiological state, such as late-stage pregnancy. Where use is permitted, populations like the geriatric group or those with mild organ impairment are explicitly labeled for conditional use, requiring careful consideration according to the official product information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Loxidol's (Meloxicam) interaction profile based on risks associated with co-administration, primarily involving pharmacodynamic and pharmacokinetic mechanisms.


Documented Interaction Categories

Classification Examples of Interacting Agents
Increased Bleeding/Ulceration Risk Oral Anticoagulants (e.g., Warfarin), other NSAIDs, Corticosteroids, SSRIs/SNRIs.
Increased Plasma Concentration Risk Lithium, Methotrexate, Cyclosporine.
Reduced Efficacy Risk Diuretics (e.g., Furosemide), ACE-inhibitors, Angiotensin Receptor Blockers (ARBs).

Official Restrictions and Constraints

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (including COX-2 inhibitors) and analgesic doses of Aspirin is not generally recommended due to an additive risk of serious gastrointestinal adverse events. With Oral Anticoagulants, co-administration carries an increased risk of serious bleeding complications. Meloxicam may increase the plasma concentrations of Lithium and Methotrexate by reducing their renal clearance, raising the potential for toxicity. Furthermore, concurrent use with ACE-inhibitors and Diuretics may diminish their antihypertensive or natriuretic effects. Alcohol consumption should be avoided as it increases the risk of gastrointestinal bleeding. A specific constraint notes that the Meloxicam oral suspension is not recommended for co-administration with Sodium Polystyrene Sulfonate (Kayexalate).

Mechanism of Action

How Loxidol Works: The Mechanistic Process

Loxidol's active molecule functions as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. COX-2 is primarily responsible for the rapid conversion of arachidonic acid into pro-inflammatory mediators. This targeted molecular interaction initiates a cascade interference that results in a profound reduction in the biosynthesis and local concentration of these mediators, such as PGE2, at the peripheral tissue level.

Inhibiting COX-2 significantly alters the dynamics of two key systems: peripheral pain signaling (nociception) and central thermoregulation. The reduced PGE2 concentration affects the sensitization of peripheral nociceptors and modulates the central mechanisms that control the body's temperature set-point.

This principle of preferential action is constrained by drug concentration. At higher systemic levels, the compound increasingly affects the constitutive COX-1 enzyme, which is responsible for homeostatic functions, including the generation of prostaglandins vital for maintaining renal blood flow and gastric mucosal integrity. The potential for non-selective action is tied to the drug's concentration profile.

Dosage and Administration Information

Loxidol is administered through two recognized routes: the oral route (tablets, capsules, or suspension) and by intravenous (IV) injection. The use pattern is structured around a once-daily schedule for all forms.

Official Dosing and Administration

Parameter Administration Details
Standard Oral Dosing Standard adult dosing begins at 7.5 mg once daily (tablets/suspension) or 5 mg once daily (capsules). The dose may be increased, but the maximum daily limit is 15 mg for tablets/suspension and 10 mg for capsules.
IV Dosing The intravenous injection is administered as a 30 mg dose once daily by a healthcare professional.
Frequency and Timing The total daily amount for all forms is administered once daily. The oral dose may be taken during a meal or without regard to the timing of meals.
Population Adjustments For patients with severe renal impairment who are on hemodialysis, the maximum oral dose is restricted to 7.5 mg per day. Pediatric dosing is weight-based, with a maximum daily limit of 7.5 mg.

The overall use protocol requires that Loxidol be used for the shortest duration necessary, consistent with treatment goals. Furthermore, the IV form is administered as a rapid bolus injection over 15 seconds, and patients must be well hydrated prior to administration. It is important to note that the different oral formulations are not considered interchangeable due to varying systemic absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Loxidol

Evidence for use in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

The research exploring the use of Loxidol for symptomatic contexts related to joint conditions involves two forms of arthritis: Osteoarthritis (OA) and adult Rheumatoid Arthritis (RA). Studies conducted during periods of increased symptom activity in adult patients with OA included Randomized Controlled Trials (RCTs). These RCTs, along with compiled Meta-analyses, were used in research exploring how symptoms are measured over defined time intervals.

In these studies, research examined patient-reported outcomes describing perceived discomfort, focusing on measuring pain intensity and functional capacity, such as movement limitations or joint stiffness. Findings describe patterns observed in the studies where patients reported measurements of these symptomatic outcomes when compared against an inactive substance (placebo) or other standard treatments. The studies tracked symptomatic data in the observed populations during the short- to intermediate-term follow-up periods, typically lasting from four weeks up to six months.

For Rheumatoid Arthritis in adults, research tracked outcomes related to functional measures and phases of heightened symptom activity, using composite criteria like the ACR 20 response. The studies explored patterns of symptomatic data linked to inflammatory or irritative states, such as the number of tender or swollen joints. This evidence contributes to the broader evidence landscape by providing context on short-term symptomatic measurement, and these findings do not determine whether the underlying disease course itself is altered.


Evidence for use in Ankylosing Spondylitis (AS)

Loxidol was studied in research contexts involving symptoms of Ankylosing Spondylitis (AS), a condition characterized by fluctuating or episodic manifestations. The evidence base includes controlled RCTs and short-term crossover comparisons. The research examined temporary physiological imbalance and physical discomfort.

Studies tracked changes in the composite Ankylosing Spondylitis Disease Activity Score (ASDAS), alongside functional measures and patient-reported pain levels. This research provides insight into short-term symptomatic data, with controlled comparison periods sometimes lasting as short as four weeks.


Evidence in Pediatric Populations (Juvenile Rheumatoid Arthritis)

For Juvenile Rheumatoid Arthritis (JRA), Loxidol was examined in a specific population: pediatric patients aged 2 years and older. The studies conducted involved controlled comparisons against an active NSAID, along with necessary Pharmacokinetic (PK) trials. Research explored short-term symptomatic measurement, focusing on outcomes reflecting daily functioning and activity level.


What is Still Uncertain About Loxidol's Research Base

Key research limitation frames include the fact that follow-up durations were limited across many indications, focusing on immediate symptomatic data rather than long-term disease evolution. The evidence base has explored symptomatic management, but comparative evidence is limited against some other available drug therapies in the same class.

Frequently Asked Questions (FAQ)

Common questions about Loxidol (FAQ)

Q: Does Loxidol make you feel tired or drowsy?

A: Regulatory documents describe side effects that may affect the central nervous system, such as dizziness, headache, confusion, and disorientation. Official information indicates that these effects may influence daily activities.


Q: Can Loxidol be taken if I am already taking over-the-counter pain relievers?

A: Official information advises caution and generally does not recommend taking Loxidol concurrently with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin. This is due to a documented risk of serious gastrointestinal events when combining these medicines.


Q: Are there any common foods or drinks that should be avoided while using Loxidol?

A: Official materials restrict the concurrent use of alcohol due to the documented risk of significantly increasing gastrointestinal bleeding. Additionally, some regulatory documents may mention cautions regarding grapefruit or grapefruit juice.


Q: Can Loxidol cause issues with my stomach or digestion?

A: Official documentation lists effects on the Gastrointestinal System as the most common reported side effects. These include symptoms such as dyspepsia (indigestion), nausea, abdominal pain, and diarrhoea.


Q: Is Loxidol known to interact with birth control pills?

A: Regulatory information notes a potential interaction with certain oral contraceptives containing drospirenone. Because this combination may increase potassium levels in the blood, official labeling includes specific precautions.


Q: Are there any known interactions between Loxidol and herbal supplements?

A: Some authoritative sources note a potential for increased bleeding risk when the drug is taken concurrently with certain herbal supplements. An example sometimes cited is ginkgo (ginkgo biloba).


Q: Does Loxidol affect your mood or cause anxiety?

A: Official documents list mood disturbances (e.g., mood disorders) and other psychiatric events, such as nightmares and confusion, as possible documented adverse reactions. These effects are typically reported as less common.


Q: Does Loxidol have any warnings about driving or operating machinery?

A: Regulatory documents include warnings stating that if the medicine causes side effects such as dizziness, vertigo, or visual disturbances, activities such as driving or operating machines must be avoided. This is a standard safety precaution for drugs that may affect alertness or coordination.


Q: How long does it typically take to notice the effects of Loxidol?

A: Clinical studies described in regulatory documents indicate that the drug begins its therapeutic effect soon after administration. Measurements of symptomatic outcomes in studies often tracked changes within the first few days or one week of continuous use.


Q: Is Loxidol safe to use for a long period of time?

A: Official documentation requires that the drug be used for the shortest duration possible consistent with treatment goals. This is based on the fact that the risk of serious cardiovascular and gastrointestinal adverse events may be associated with longer duration of use.


Q: Why do some people say Loxidol is for one condition and others say it's for another?

A: The medicine is officially approved to treat the signs and symptoms of multiple inflammatory conditions, which explains the variety of reported uses. These approved indications include Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Juvenile Rheumatoid Arthritis.


Q: Does Loxidol affect your sleep schedule?

A: Regulatory documents list sleep disturbances or nightmares as possible, though generally less common, adverse reactions.


Q: Is it normal to feel a change in appetite when starting Loxidol?

A: A change in appetite is not listed among the very common side effects. However, regulatory documents state that a loss of appetite has been reported as a symptom associated with rare, severe adverse reactions like hepatitis (liver inflammation).


Q: Is there a generic version of Loxidol available?

A: The active ingredient in Loxidol, known as Meloxicam, is widely available as a generic version. This generic form is approved and available in the same dosage forms as the trade name product.


Q: Is Loxidol studied for use in children or adolescents?

A: Official regulatory documents confirm the approved use of the medicine for pediatric patients aged 2 years and older. This specific use is for certain forms of Juvenile Rheumatoid Arthritis (JRA).


Q: Do I need to stop taking Loxidol gradually, or can I stop suddenly?

A: Official documents note that the drug should not be abruptly discontinued when used to manage certain chronic conditions. This is a matter that requires the consultation of a healthcare professional.


Q: How does the time of day I take Loxidol affect its effectiveness?

A: The drug is prescribed for a once-daily schedule and clinical data shows it has a long elimination half-life of approximately 20 hours. This long half-life helps maintain stable drug concentrations in the body throughout the 24-hour period.


Q: How long does Loxidol stay in your system?

A: The medicine has a plasma elimination half-life of approximately 20 hours. The half-life describes the amount of time it takes for half of the drug to be eliminated from the body.


Q: Is there any difference in how Loxidol works between men and women?

A: Regulatory documents note a difference in the drug's concentration profiles (pharmacokinetics) between elderly females and other patient populations. However, the adverse event profile is generally considered comparable across sexes.


Q: Can Loxidol be crushed or cut in half?

A: Official patient instructions specify that the oral tablet formulations are generally intended to be swallowed whole. Regulatory labeling typically indicates that crushing, cutting, or chewing is restricted unless the tablet is specifically scored for splitting, as modification can affect how the medicine is absorbed.


Q: Does Loxidol require any specific monitoring or blood tests?

A: Regulatory documents describe a requirement for patients on long-term treatment to be monitored periodically. This monitoring typically involves checking for potential effects on renal (kidney) and hepatic (liver) function.


Q: Does Loxidol interact with other mental health medications?

A: Regulatory documents identify an interaction with specific mental health medications, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs). This interaction is due to a documented increased risk of serious bleeding complications.


Q: Is it possible to develop a tolerance to Loxidol over time?

A: Regulatory documents for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) typically do not contain warnings regarding the development of physical tolerance or dependence. The drug is not classified as a controlled substance.


Q: What are the symptoms of an allergic reaction to Loxidol?

A: Official documents describe the signs of a severe allergic reaction as potentially including blistering or peeling of the skin (like Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis), swelling of the face, lips, or throat (angioedema), and breathing difficulties.


Q: Is Loxidol used to treat chronic or acute conditions?

A: The drug is indicated for the relief of the signs and symptoms of long-term inflammatory conditions. These include conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.


Q: Can Loxidol affect blood pressure?

A: Regulatory documents note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) can lead to the new onset of hypertension (high blood pressure) or the worsening of pre-existing hypertension. For this reason, official labeling includes a requirement for blood pressure monitoring during treatment.


Q: What are the restrictions on using Loxidol with alcohol?

A: Official documents explicitly prohibit or restrict the concurrent use of alcohol. This prohibition is based on the documented risk that alcohol significantly increases the risk of serious gastrointestinal bleeding when combined with this medicine.


Q: What are the typical expectations for Loxidol's peak effect?

A: Regulatory documents describe the maximum plasma concentration ( C max) of the medicine is typically reached in the body approximately 4 to 5 hours after an oral dose. This concentration corresponds to the drug's peak level in the bloodstream.

How should Loxidol be stored and disposed of?

How to Store and Dispose of Loxidol (Meloxicam)

Loxidol must be stored according to official requirements to preserve its stability and effectiveness, strictly avoiding prohibited environmental conditions.

Storage Requirements

The medicine should be kept at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). It is mandatory to keep Loxidol from freezing and to protect the container from light and moisture. Oral forms must be kept in a tightly closed container.

Stability and Safety

All Loxidol preparations must be stored out of the sight and reach of children. The injectable solution must be visually inspected and discarded if it appears discolored or contains any particulate matter. Do not keep the medicine past its expiration date.

Disposal Instructions

Unused or expired Loxidol must be disposed of according to local regulatory requirements. Patients should consult a pharmacist or healthcare professional for specific guidance on discarding the product safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loxidol found in:

A-Z Index: